DaVita Inc. $DVA Stock Position Decreased by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments cut its stake in DaVita by 63.4% in Q4, selling 11,671 shares and ending the period with 6,738 shares worth about $766,000, while institutional investors own roughly 90.12% of the stock.
• DaVita beat Q4 estimates, reporting $3.40 EPS versus $3.24 expected and $3.62 billion in revenue (up 9.9% year-over-year), and set FY2026 guidance of 13.60–15.00 EPS with analysts averaging ~14.16 EPS and a $155.80 price target.

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 63.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,738 shares of the company's stock after selling 11,671 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in DaVita were worth $766,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Elevation Wealth Partners LLC boosted its stake in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock worth $31,000 after acquiring an additional 165 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of DaVita during the 2nd quarter worth $43,000. iSAM Funds UK Ltd bought a new stake in shares of DaVita during the 3rd quarter worth $46,000. Stance Capital LLC bought a new stake in shares of DaVita during the 3rd quarter worth $47,000. Finally, SJS Investment Consulting Inc. lifted its holdings in shares of DaVita by 3,091.7% in the third quarter. SJS Investment Consulting Inc. now owns 383 shares of the company's stock valued at $51,000 after purchasing an additional 371 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Trading Down 2.1%

Shares of NYSE:DVA opened at $151.80 on Friday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $159.42. The business has a fifty day simple moving average of $150.92 and a 200 day simple moving average of $130.74. The firm has a market cap of $10.14 billion, a price-to-earnings ratio of 15.32, a P/E/G ratio of 0.54 and a beta of 0.92.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the company earned $2.24 earnings per share. DaVita's quarterly revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 14.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Truist Financial set a $158.00 target price on DaVita in a report on Thursday, February 5th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Weiss Ratings restated a "hold (c)" rating on shares of DaVita in a report on Monday, December 29th. Barclays increased their target price on DaVita from $143.00 to $158.00 and gave the company an "equal weight" rating in a report on Tuesday, February 3rd. Finally, Zacks Research lowered DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, DaVita presently has an average rating of "Hold" and an average price target of $155.80.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.